Diagnostic markers for glioblastoma.
作者： C S Jung , C Hartmann , A W Unterberg
DOI: 10.14670/HH-26.1327
关键词: Surgical resection 、 Diagnostic marker 、 Tumor tissue 、 Chemotherapy 、 MEDLINE 、 Glioblastoma 、 Pathology 、 Medicine 、 Proteomics
摘要: Glioblastoma (GBM) is the most malignant form of cerebral gliomas, and despite distinct progress in surgical resection, radiation chemotherapy, prognosis patients with GBM still very poor. In past decades knowledge genomics proteomics diagnostic, prognostic, predictive pharmakodynamic markers measured cerebrospinal-fluid (CSF), serum, or tumor tissue biomarkers has improved. This review briefly compiles our concepts on diagnostic for GBM, focusing latest developments.
unirioja.es
um.es
sci-hub.st 参考文章(136)
Ping-Pin Zheng, Theo M. Luider, Rob Pieters, Cees J.J. Avezaat, Martin J. van den Bent, Peter A.E. Sillevis Smitt, Johan M. Kros, Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors. Journal of Neuropathology and Experimental Neurology. ,vol. 62, pp. 855- 862 ,(2003) , 10.1093/JNEN/62.8.855
Jürgen A. Kraus, Katrin Lamszus, Nicole Glesmann, Martina Beck, Marietta Wolter, Michael Sabel, Dietmar Krex, Thomas Klockgether, Guido Reifenberger, Uwe Schlegel, Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathologica. ,vol. 101, pp. 311- 320 ,(2001) , 10.1007/S004010000258
Peter C. Burger, Dennis K. Pearl, Kenneth Aldape, Allan J. Yates, Bernd W. Scheithauer, Sandra M. Passe, Robert B. Jenkins, C. David James, Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme? Journal of Neuropathology and Experimental Neurology. ,vol. 60, pp. 1099- 1104 ,(2001) , 10.1093/JNEN/60.11.1099
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework* Clinical Pharmacology & Therapeutics. ,vol. 69, pp. 89- 95 ,(2001) , 10.1067/MCP.2001.113989
Kokunai T, Taomoto K, Matsumoto S, Tamaki N, Okuda T, Hashimoto N, The value of neuron specific enolase (NSE) in patients with brain tumors Nō to shinkei Brain and nerve. ,vol. 39, pp. 169- ,(1987)
Kazuo Hamaya, Akira Nishimoto, Kenji Doi, Toshio Tanaka, The determination of glial fibrillary acidic protein for the diagnosis and histogenetic study of central nervous system tumors: a study of 152 cases. Acta Medica Okayama. ,vol. 39, pp. 453- 462 ,(1985) , 10.18926/AMO/31509
Manfred Herrmann, Hannelore Ehrenreich, Brain derived proteins as markers of acute stroke : Their relation to pathophysiology, outcome prediction and neuroprotective drug monitoring Restorative Neurology and Neuroscience. ,vol. 21, pp. 177- 190 ,(2003)
Gaspar Kitange, David N. Louis, Loki Johnk, Robert B. Jenkins, Yanhong Wu, Christian Hartmann, Linda K. Ashworth, Linda K. Ashworth, Transcript Map of the 3.7-Mb D19S112–D19S246 Candidate Tumor Suppressor Region on the Long Arm of Chromosome 19 Cancer Research. ,vol. 62, pp. 4100- 4108 ,(2002)
Shinji Fukui, Hiroshi Nawashiro, Naoki Otani, Hidetoshi Ooigawa, Namiko Nomura, Akiko Yano, Takahito Miyazawa, Akira Ohnuki, Nobusuke Tsuzuki, Hiroshi Katoh, Shoichiro Ishihara, Katsuji Shima, Nuclear accumulation of basic fibroblast growth factor in human astrocytic tumors Cancer. ,vol. 97, pp. 3061- 3067 ,(2003) , 10.1002/CNCR.11450
Shizuo Shirai, Shingo Takano, Hideo Suzuki, Shinichi Kondo, Tooru Maruno, Yoshihiko Yoshii, Tadao Nose, Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients Cancer Research. ,vol. 56, pp. 2185- 2190 ,(1996)